e-learning
resources
Barcelona 2010
Wednesday, 22.09.2010
Aspects of severe asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Dose response to inhaled fluticasone/salmeterol measured with extended exhaled nitric oxide in refractory asthma
P. Williamson, S. Vaidyanathan, K. Clearie, B. Lipworth (Dundee, United Kingdom)
Source:
Annual Congress 2010 - Aspects of severe asthma
Session:
Aspects of severe asthma
Session type:
E-Communication Session
Number:
5481
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Williamson, S. Vaidyanathan, K. Clearie, B. Lipworth (Dundee, United Kingdom). Dose response to inhaled fluticasone/salmeterol measured with extended exhaled nitric oxide in refractory asthma. Eur Respir J 2010; 36: Suppl. 54, 5481
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Optimising inhaled corticosteroid (ICS) dose using exhaled nitric oxide (eNO) measurements
Source: Eur Respir J 2003; 22: Suppl. 45, 34s
Year: 2003
Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children
Source: Eur Respir J 2002; 20: 630-634
Year: 2002
Predicting response to corticosteroid in COPD using exhaled nitric oxide
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
Effect of once-daily inhaled glucocorticosteroid administration on exhaled nitric oxide in controlled asthma patients
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008
The relationship between exhaled nitric oxide and compliance/adherence in patients with bronchial asthma using inhaled corticosteroids
Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases
Year: 2012
Exhaled nitric oxide and inhaled corticosteroid dose reduction in asthma: a cohort study
Source: Eur Respir J 2014; 44: 1705-1707
Year: 2014
Effect of adding montelukast to budesonide treatment on exhaled nitric oxide in mild to moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 259s
Year: 2004
Changes of exhaled nitric oxide during steroid treatment of childhood asthma
Source: Eur Respir J 2002; 19: 1015-1019
Year: 2002
Tapering oral corticosteroids in severe asthma is associated with a decrease in fractional exhaled nitric oxide
Source: Annual Congress 2011 - Mechanism and monitoring of airway diseases
Year: 2011
Comparison of long-acting inhaled beta2–agonists plus inhaled steroids versus increasing dose of inhaled steroids on exhaled nitric oxide among asthmatic children poorly controlled
Source: Eur Respir J 2005; 26: Suppl. 49, 617s
Year: 2005
Fractional exhaled nitric oxide (FeNO) could be a good predictor for the effectiveness of inhaled corticosteroid (ICS) in patients with COPD
Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases
Year: 2009
The effect of inhaled corticosteroid therapy on exhaled nitric oxide and exhaled hydrogen peroxide in asthma patients
Source: Annual Congress 2006 - Monitoring airway inflammation – exhaled markers
vs
induced sputum
Year: 2006
Effect of inhaled steroids and long-acting β2 agonists on exhaled nitric oxide (eNO) in asthmatic children
Source: Eur Respir J 2004; 24: Suppl. 48, 270s
Year: 2004
Exhaled nitric oxide and inhaled steroids in patients with stable asthma in primary care
Source: Annual Congress 2003 - Recognition, management and assessment of asthma including severe asthma
Year: 2003
Measurement of exhaled nitric oxide can not reliably predict exacerbations in school-aged asthmatic children using inhaled corticosteroids
Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma
Year: 2009
Are exhaled nitric oxide and airway hyperresponsiveness good predictive markers of inhaled corticosteroids dose reduction failures in children?
Source: Annual Congress 2003 - Role of exhaled NO in diagnosis and therapy of childhood asthma
Year: 2003
Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma
Source: Eur Respir J 2010; 35: 1221-1227
Year: 2010
Utility of fractional exhaled nitric oxide (FeNO) in assessing asthma control following inhaled corticosteroid treatment
Source: International Congress 2016 – Assessing lower airway inflammation with different tools
Year: 2016
Bronchial nitric oxide output predicts responsiveness to inhaled steroids in COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 429s
Year: 2004
Stability of exhaled nitric oxide (F
E
NO) in patients with severe, steroid-dependent asthma
Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept